Study #2022-0491
A phase 1b/2, open-label study of Amivantamab Monotherapy and in addition to standard-of-care Chemotherapy in participants with advanced or metastatic Colorectal Cancer.
MD Anderson Study Status
Enrolling
Treatment Agent
Amivantamab, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan
Description
The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to characterize the safety of amivantamab when added to standard-of care (SoC) chemotherapy in participants with metastatic colorectal cancer (mCRC) (Ph2 cohorts), and to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced or Metastatic Colorectal Cancer
Study phase:
Physician name:
Kanwal Raghav
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-855-773-0951
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.